9.3 USD
-0.14 (-1.48%)
9.24 USD
-0.06 (-0.65%)
ChartMill assigns a Buy % Consensus number of 74% to NTLA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 22.12. This target is 137.9% above the current price.
NTLA was analyzed by 31 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about NTLA.
In the previous month the buy percentage consensus was at a similar level.
NTLA was analyzed by 31 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-12 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2025-11-11 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-11-11 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2025-11-10 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-07 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-07 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-11-07 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-07 | Wedbush | Maintains | Neutral -> Neutral |
| 2025-11-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-07 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-28 | Bernstein | Downgrade | Outperform -> Market Perform |
| 2025-10-28 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-10-28 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-10-28 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-28 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-10-27 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-27 | B of A Securities | Maintains | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-06 | JMP Securities | Upgrade | Market Perform -> Market Outperform |
| 2025-09-19 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-09-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-03 | Canaccord Genuity | Maintains | Buy -> Buy |
INTELLIA THERAPEUTICS INC / NTLA FAQ
What is the average price target for INTELLIA THERAPEUTICS INC (NTLA) stock?
31 analysts have analysed NTLA and the average price target is 22.12 USD. This implies a price increase of 137.9% is expected in the next year compared to the current price of 9.3.
What is the consensus rating for NTLA stock?
The consensus rating for INTELLIA THERAPEUTICS INC (NTLA) is 73.5484 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed INTELLIA THERAPEUTICS INC (NTLA)?
The number of analysts covering INTELLIA THERAPEUTICS INC (NTLA) is 31.